Your session is about to expire
← Back to Search
Peripheral Blood Stem Cell Transplantation for Acute Leukemia
Study Summary
This trial gives cancer patients astatine-211, a radioactive substance, before their donor stem cell transplant. The hope is that the astatine will kill the cancer cells while having less of an effect on the healthy cells.
- Acute Leukemia
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Acute Myelogenous Leukemia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any other scientific papers which have researched Cyclosporine?
"At this time, 599 clinical trials are underway that focus on cyclosporine. Of these, 58 are in phase 3. Many of the trials for cyclosporine are based in Philadelphia, Pennsylvania; however, there are 5940 locations running studies for this treatment across the globe."
Is this research project only testing people who are under 40 years old?
"The age requirements to participate in this study are between 18-75 years old."
Are investigators still looking for study participants?
"This study, which was originally posted on October 24th 2017, is still actively recruiting participants according to information found on clinicaltrials.gov. The listing was last updated on August 29th 2022."
How is Cyclosporine most often used to help patients?
"Cyclosporine is often used to treat lymphoma, non-hodgkin. Other potential benefits of taking cyclosporine include prevention of stem cell transplant rejection, interstitial cystitis treatment, and managing nephrotic syndrome."
Share this study with friends
Copy Link
Messenger